Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
Oragenics, Inc. filed this Current Report on Form 8-K on December 30, 2009, to disclose a material definitive agreement involving a private placement of equity. The company is incorporated in Florida and operates from its principal executive offices in Jacksonville, Florida.
Key Financial Metrics and Transaction Details
The filing details a financing transaction consummated on December 30, 2009, with the following specific metrics:
- Total Equity Issued: 10,016,250 shares of Common Stock.
- Price Per Share: $0.25.
- Total Consideration Received: $2,504,062.50.
- Cash Proceeds: $2,450,000 received at closing.
- Non-Cash Consideration: $54,062.50 satisfied via cancellation of deferred compensation owed to Dr. Jeffrey Hillman.
- Debt Cancellation: A $1.0 million secured note held by the Koski Family Limited Partnership (KFLP) was cancelled in exchange for 4,000,000 shares issued at $0.25 per share.
- Warrant Exercises: KFLP exercised warrants for 1,000,000 shares at $0.10 per share; Directors Christine L. Koski and Robert C. Koski exercised options for 100,000 shares each at $0.10 per share.
The filing does not provide comprehensive revenue, profit, cash flow, or margin data for the reporting period, as this is an event-driven report rather than a periodic financial statement.
Material Changes Versus Prior Period
The primary material change is the reduction of debt and the increase in equity capital:
- Debt Reduction: Elimination of a $1.0 million secured note that previously carried interest at Prime plus 4.0% and was secured by substantially all company assets (excluding receivables).
- Capital Structure: Significant dilution through the issuance of over 10 million new shares and the exercise of warrants and options.
- Liquidity: Immediate injection of $2.45 million in cash.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the disclosure of the transaction terms. The transactions were executed under Section 4(2) of the Securities Act of 1933 as private placements not involving a public offering.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the status of the cancelled $1.0 million secured note and the release of asset liens.
- Review the attached press release (Exhibit 99.1) for additional context on the use of proceeds.
- Check subsequent filings for the impact of this capital raise on the company's cash runway and operational milestones.